This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Latest News
-
12th March 2024
ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
-
29th February 2024
ARECOR ANNOUNCES LAUNCH OF OGLUO® IN THE NETHERLANDS
-
23rd January 2024
ARECOR ANNOUNCES UPDATE ON INBRX-101
News
-
12/03/2024
ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
-
29/02/2024
ARECOR ANNOUNCES LAUNCH OF OGLUO® IN THE NETHERLANDS
-
23/01/2024
ARECOR ANNOUNCES UPDATE ON INBRX-101
-
18/01/2024
ARECOR GRANTED KEY EUROPEAN PATENT EXTENDING PROTECTION FOR INSULIN PRODUCTS, AT278 AND AT247
-
08/01/2024
ARECOR ANNOUNCES EXPANSION OF EXISTING SPECIALTY HOSPITAL FORMULATION COLLABORATION
-
03/01/2024
ARECOR APPOINTS DR HELEN PARRIS AS SVP, COMMERCIAL & GENERAL MANAGER OF TETRIS PHARMA LTD.